X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7639) 7639
Book Chapter (192) 192
Newsletter (26) 26
Reference (6) 6
Magazine Article (5) 5
Publication (5) 5
Newspaper Article (3) 3
Transcript (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5952) 5952
science & technology (5789) 5789
life sciences & biomedicine (5594) 5594
male (3287) 3287
female (2861) 2861
hypertension (2424) 2424
angiotensin (2222) 2222
middle aged (2195) 2195
cardiovascular system & cardiology (2134) 2134
angiotensin-converting enzyme inhibitors - therapeutic use (2107) 2107
hypertension - drug therapy (2093) 2093
aged (1977) 1977
angiotensin ii type 1 receptor blockers - therapeutic use (1665) 1665
animals (1553) 1553
treatment outcome (1484) 1484
antihypertensive agents - therapeutic use (1466) 1466
pharmacology & pharmacy (1295) 1295
risk factors (1277) 1277
blood pressure - drug effects (1256) 1256
cardiac & cardiovascular systems (1242) 1242
adult (1201) 1201
heart failure (1195) 1195
renin-angiotensin system - drug effects (1130) 1130
drug therapy (1116) 1116
drug therapy, combination (1092) 1092
medicine & public health (1057) 1057
blood pressure (1015) 1015
peripheral vascular disease (1015) 1015
angiotensin ii type 1 receptor blockers - adverse effects (966) 966
hypertension - physiopathology (878) 878
tetrazoles - therapeutic use (860) 860
angiotensin-converting enzyme inhibitors - adverse effects (840) 840
diabetes (811) 811
abridged index medicus (793) 793
enzymes (788) 788
cardiology (762) 762
heart failure - drug therapy (737) 737
antihypertensive agents - adverse effects (735) 735
ace inhibitors (731) 731
research (716) 716
care and treatment (696) 696
internal medicine (685) 685
mortality (682) 682
angiotensin ii (671) 671
renin-angiotensin system (655) 655
health aspects (642) 642
general & internal medicine (626) 626
analysis (625) 625
aged, 80 and over (614) 614
medicine, general & internal (600) 600
angiotensin ii type 1 receptor blockers - pharmacology (580) 580
double-blind method (580) 580
urology & nephrology (573) 573
rats (553) 553
cardiovascular disease (551) 551
time factors (548) 548
angiotensin receptor antagonists - therapeutic use (541) 541
tetrazoles - adverse effects (538) 538
hypertension - complications (529) 529
adrenergic beta-antagonists - therapeutic use (520) 520
prospective studies (519) 519
angiotensin ii type 1 receptor blockers - administration & dosage (509) 509
cardiovascular diseases (506) 506
benzimidazoles - therapeutic use (492) 492
diuretics (488) 488
renin-angiotensin system - physiology (488) 488
angiotensin-converting enzyme inhibitors - pharmacology (481) 481
clinical trials (472) 472
angiotensin receptor antagonists (459) 459
cardiovascular (458) 458
randomized controlled trials as topic (458) 458
kidney diseases (457) 457
medicine (457) 457
calcium channel blockers - therapeutic use (456) 456
antihypertensive agents - administration & dosage (452) 452
valsartan (452) 452
enzyme inhibitors (450) 450
angiotensin-converting enzyme inhibitors - administration & dosage (444) 444
angiotensin-converting enzyme inhibitors (435) 435
renin (427) 427
patients (423) 423
dosage and administration (412) 412
heart failure - physiopathology (409) 409
aldosterone (405) 405
dose-response relationship, drug (405) 405
antihypertensive agents - pharmacology (404) 404
diuretics - therapeutic use (400) 400
follow-up studies (389) 389
rodents (378) 378
retrospective studies (370) 370
nephrology (366) 366
studies (365) 365
valine - analogs & derivatives (359) 359
physiological aspects (345) 345
review (344) 344
pharmacology/toxicology (343) 343
diabetes mellitus (338) 338
clinical trials as topic (337) 337
heart attacks (336) 336
heart diseases (335) 335
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7726) 7726
German (78) 78
Japanese (44) 44
Spanish (25) 25
French (22) 22
Russian (13) 13
Portuguese (11) 11
Chinese (8) 8
Norwegian (5) 5
Danish (4) 4
Swedish (4) 4
Czech (3) 3
Italian (3) 3
Dutch (2) 2
Hungarian (2) 2
Polish (2) 2
Romanian (2) 2
Korean (1) 1
Serbian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2009, Volume 361, Issue 1, pp. 40 - 51
.... Early blockade of the renin–angiotensin system did not modify nephropathy progression in patients with type 1 diabetes but had important effects in slowing retinopathy... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Retina - drug effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Male | Albuminuria | Angiotensin II Type 1 Receptor Blockers - pharmacology | Enalapril - therapeutic use | Enalapril - adverse effects | Mesangial Cells - drug effects | Glomerular Filtration Rate - drug effects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Adult | Female | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Diabetic Nephropathies - prevention & control | Double-Blind Method | Diabetes Mellitus, Type 1 - physiopathology | Kidney Glomerulus - drug effects | Diabetes Mellitus, Type 1 - pathology | Kaplan-Meier Estimate | Losartan - pharmacology | Logistic Models | Kidney Glomerulus - pathology | Disease Progression | Diabetes Mellitus, Type 1 - drug therapy | Diabetic Retinopathy - prevention & control | Enalapril - pharmacology | Losartan - therapeutic use | Mesangial Cells - pathology | Losartan - adverse effects | Renin-Angiotensin System - drug effects | Retina - pathology | Diabetic retinopathy | Control | Usage | Enalapril | Type 1 diabetes | Patient outcomes | Losartan | Enalaprilat | Drug therapy | Kidneys | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9647, pp. 1394 - 1402
.... We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Severity of Illness Index | Diabetic Retinopathy - drug therapy | Angiotensin II Type 1 Receptor Blockers - adverse effects | Double-Blind Method | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Diabetic Retinopathy - classification | Male | Treatment Outcome | Diabetes Mellitus, Type 1 - complications | Diabetes Mellitus, Type 1 - drug therapy | Adolescent | Adult | Female | Tetrazoles - therapeutic use | Diabetic Retinopathy - etiology | Tetrazoles - adverse effects | Benzimidazoles - adverse effects | Insulin - therapeutic use | Benzimidazoles - therapeutic use | Prevention | Diabetic retinopathy | Complications and side effects | Candesartan | Type 1 diabetes | Dosage and administration | Drug therapy | Risk factors | Studies | Clinical trials | Photographs | Diabetes | Pressure measurement | Patients | Index Medicus | Abridged Index Medicus | Benzimidazoles | Tetrazoles | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | Hypoglycemic Agents | MEDICAL AND HEALTH SCIENCES | Type 1 | drug therapy | complications | Diabetes Mellitus | classification | Insulin | etiology | adverse effects | therapeutic use | Diabetic Retinopathy
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2008, Volume 358, Issue 15, pp. 1547 - 1559
This large trial compared the angiotensin-receptor blocker telmisartan, the angiotensin-converting... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzoates - adverse effects | Angiotensin II Type 1 Receptor Blockers - adverse effects | Benzoates - therapeutic use | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Male | Risk | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Blood Pressure - drug effects | Ramipril - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Ramipril - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Diabetes Mellitus - drug therapy | Kaplan-Meier Estimate | Hospitalization | Creatinine - blood | Angioedema - chemically induced | Aged | Complications and side effects | Ramipril | Drug therapy, Combination | Diabetes | Cardiovascular diseases | Drug therapy | Comparative analysis | Risk factors | Telmisartan | Clinical trials | Vein & artery diseases | Cardiovascular disease | Pharmacology | Clinical outcomes | Index Medicus | Abridged Index Medicus | Blood Pressure | Benzimidazoles | Cardiovascular Diseases | MEDICIN OCH HÄLSOVETENSKAP | Angiotensin II Type 1 Receptor Blockers | epidemiology | Angiotensin-Converting Enzyme Inhibitors | Combination | MEDICAL AND HEALTH SCIENCES | Creatinine | chemically induced | Benzoates | drug therapy | Angioedema | drug effects | Diabetes Mellitus | blood | adverse effects | mortality | therapeutic use | Kaplan-Meiers Estimate
Journal Article